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Anxiety and depression in diabetes 
care: longitudinal associations with 
health-related quality of life
Xiaona Liu  1,4 ✉, Juanita Haagsma1, Eric Sijbrands  2, Hanneke Buijks2,3, Laura Boogaard1, 
Johan P. Mackenbach1, Vicki erasmus1 & Suzanne polinder1
Anxiety and depression are commonly found in patients with diabetes, but little is known about 
how the anxiety and depression symptoms of diabetes patients and the health-related quality of 
life (HRQoL) over time influence each other. Therefore, we conducted a survey among patients with 
diabetes (T1) and repeated the survey after 3 months (T2). Linear regression models and cross-lagged 
structural equation models were used to analyze the associations between anxiety and depression 
symptoms and HRQoL within and across time intervals. Correcting for baseline index and potential 
confounders, the HRQoL index at T2 reflected the change in anxiety/depression between T1 and T2 
more than anxiety/depression at T1 (P < 0.05). Similarly, anxiety and depression at T2 reflected the 
change in the EQ-5D index over time more than the index at baseline (P < 0.05). Our longitudinal data 
fitted well in a cross-lagged model with bi-directional pathways of associations between anxiety and 
HRQoL, as well as depression and HRQoL, among adult patients with diabetes (x2/df = 1.102, P = 0.256; 
cfi = 1.000, RMSEA = 0.030). Our findings support early detection of anxiety and depression, as well as 
comprehensive efforts improving HRQoL for patients with diabetes.
Diabetes is an increasing health problem, especially in Western countries1,2. In 2000, the global prevalence of 
diabetes for all age groups was estimated at 2.8% whereas the expected prevalence in 2030 is 4.4%1. In recent 
years, health-related quality of life (HRQoL) has become one of the major indicators for the health assessment of 
diabetes care. Improving diabetics’ HRQoL has been considered an important goal of prevention and treatment. 
HRQoL incorporates physical, psychological and social functioning dimensions3. Despite a growing understand-
ing of clinical and laboratory measures to improve HRQoL for diabetes patients4,5, few attempts have been made 
to rigorously study the relationship between HRQoL and psychological factors, like symptoms of anxiety and 
depression, in diabetes care.
Anxiety and depression commonly exist and affect patients with diabetes2,6–10. A previous meta-analyses on 
the prevalence of depression in adults with diabetes concluded that the likelihood of depression among people 
with diabetes doubles those among a general population without diabetes7. Furthermore, evidence shows that 
symptoms of anxiety and depression often remain unrecognized in diabetes care11. Anxiety and depression may 
influence how people assess their objective health status, and impact the course of diabetes such as poor glycemic 
control and medication non-compliance12. Also, given anxiety and/or depression is an important domain of the 
broad concept of HRQoL13, it’s easily understandable that the co-occurrence of anxiety and/or depression in 
patients with diabetics may be associated with a lower HRQoL compared to patients without the co-occurrence 
of anxiety and depression.
In spite of demonstrating the negative association between anxiety/depression and HRQoL in diabetes care, 
most previous studies that have been performed on the association had used a cross-sectional design and it’s 
impossible to determine the casual relationship due to the cross-sectional nature of the studies12. As a result, there 
is little evidence that supports the relationships between anxiety/depression symptoms and HRQoL over time, 
not to mention relationships taking into account variation among different clinic and demographic subgroups 
of diabetes patients. In addition, recent studies suggest that depression is bi-directionally associated with several 
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determinants of HRQoL in diabetes care, such as obesity14, metabolic syndrome15, sexual dysfunction16, and 
severe hypoglycemic and hyperglycemic events17, however, to date it’s unknown whether or not anxiety/depres-
sion is bi-directionally associated with the overall HRQoL of diabetes.
Longitudinal data are necessary in order to assess the effect of anxiety/depression on HRQoL over time, or 
vice versa. The hypothesis in this study is that anxiety and depression are associated bi-directionally with HRQoL 
of diabetes in time. This would suggest a synchronous association between changes in anxiety/depression and 
HRQoL in diabetes care, which is perhaps similar to the relationship between fatigue and pain in primary care18. 
For example, current HRQoL of diabetes may directly predict anxiety and depressive symptoms in the future. 
Alternatively, anxiety and depression symptoms may be a consequence of experiencing different HRQoL in dia-
betes care over time.
This study aims to explore the prevalence of anxiety and depression symptoms and HRQoL in adult patients 
with diabetes in the Netherlands, and to assess associations between anxiety/depression and HRQoL in time, tak-
ing into account adult patients with different demographic and diabetes characteristics. Past evidence has shown 
that anxiety and depression are remarkably different having distinctive risks, patterns, and familial associations19. 
We therefore investigate the co-occurrence of anxiety and depression symptoms in diabetes patients separately 
in this study.
Methods
This is a prospective observational study, and it is part of an implementation study of screening and treatment of 
depression in diabetes patients following the guidelines at the Erasmus MC, University Medical Center Rotterdam 
in the Netherlands. The measurements involve digital questionnaires that were administered at baseline (T1) and 
3 months’ follow-up (T2). During the preparation phase, the participating healthcare workers received training 
from the research team, including instructions on study logistics, use of the online screening program, interpre-
tation of scores, discussion of outcomes and advising on referral to a psychologist if indicated. Study data were 
transferred and saved at the central database of the medical center throughout the project. The study protocol was 
approved by the ethics committee at the Erasmus University Medical Center Rotterdam and informed consent 
was obtained from all participants. All methods were performed in accordance with the relevant guidelines and 
regulations.
Patients. Adults (aged >18 years) who were diagnosed with type 1 or type 2 diabetes and visited the diabetes 
outpatient clinic of the hospital from November 2016 to March 2017 were invited for participation in an online 
survey, after completing a screening program for detecting their risk of depression. The implementation of the 
screening program followed Dutch National Guidelines20 and consisted of two components: a self-administrative 
anxiety and depression risk assessment, followed by a personal interview of patients who were assessed with risks 
for anxiety and/or depression. Those who indicated having difficulties to complete the online survey, due to rea-
sons including no computer access, insufficient computer skills, language barriers and cognitive problems, were 
assisted by trained nurses with tablets onsite. Patients who completed the online survey received an email with a 
link after 3 months, asking them to repeat the survey.
Measures. The self-administered digital questionnaire at T1 and T2 included the following aspects.
Demographic and diabetes characteristic. Patients were asked about their gender, age, type of diabetes, years 
living with diabetes, employment status, education background, and the country of birth of themselves and their 
parents. Individuals were defined as ethnicity of majority if both of their parents were born in the Netherlands; 
ethnicity of minority if he/she was born abroad and at least one of the parents was born abroad (1st generation), 
or if he/she was born in the Netherlands with at least one of the parents born abroad (2nd generation)21.
Anxiety and depression. The validated Dutch version of the Hospital Anxiety and Depression Scale (HADS) 
was used to detect anxiety and depression symptoms in diabetes patients22. This scale has been validated in many 
countries and its capacity to detect anxiety and depressive disorders is widely recognized23. It consists of 14 items, 
seven of which relate to anxiety symptoms and seven to depressive symptoms. Each item was scored from 0 to 3, 
therefore participants can score between 0 to 21 for either anxiety or depression. Scores at the anxiety subscale 
(HADS-A) and depression subscale (HADS-D) were measured as continuous variables in this study, except for 
the prevalence of anxiety and depression symptoms. We defined a score of 8 or more on either HADS-A or 
HADS-D to identify DSM-III anxiety and depression symptoms as suggested by Bjelland and colleagues24.
Health-related quality of life. The validated Dutch version of the five-level EuroQol five-dimensional question-
naire (EQ-5D-5L), developed by EuroQol Research Foundation, was applied to measure health-related quality 
of life (HRQoL) on five dimensions, i.e. mobility, self-care, usual activities, pain/discomfort and anxiety/depres-
sion25. Additionally, cognitive functioning was added as a sixth dimension to the five existing dimensions (EQ-
5D + C)26,27. Each dimension included five severity levels, i.e. no problems, some problems, moderate problems, 
severe problems, and extreme problems. Furthermore, the EQ visual analogue scale (VAS) was used to measure 
respondent’s self-rated health. The score ranges from 0 to 100, indicating the “the worst health you can imagine” 
to “the best health you can imagine”28. An EQ-5D summary index was calculated using scores at EQ-5D and the 
Dutch tariff established from the Dutch population13. All dimensions of EQ-5D + C were measured as categorical 
variables, while EQ VAS, EQ-5D summary index measured as continuous variables in this study.
Statistical analyses. Data were analyzed using IBM SPSS Statistics and AMOS version 24.0. Descriptive 
analyses were conducted for demographical and diabetes characteristics, anxiety and depression subscales 
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(HADS), and all dimensions of the EQ-5D + C. Paired chi-square tests and one-way analysis of variance tests 
were performed to assess differences between T1 and T2 for those variables. Also, differences in diabetes EQ-5D 
were compared by identifying if a patient filled in a different level of problems on one or more dimensions at 
T2 compared to the T1. We investigated the longitudinal associations in three steps. First, we assessed the asso-
ciation between HADS and HRQoL at T1 and T2, respectively. The mean and its 95% confidence interval (CI) 
of HADS-A and HADS-D were calculated and mapped at each of the five severity levels for the dimensions 
with anxiety/depression dimension excluded. Univariate linear regression analyses were conducted and mapped 
using HADS-A and HADS-D scores separately to explain the variation at EQ-5D summary index and EQ VAS 
score within time intervals. Second, we assessed the association across time intervals in four linear regression 
models, predicting three outcomes at T2, i.e. EQ-5D summary index (Models 1 and 2), HADS-A (Model 3) and 
HADS-D (Model 4). In the Model 1 and 2, HADS-A/HADS-D at T1 and change in HADS-A/HADS-D between 
T1 and T2 were firstly added as main predicators separately, then EQ-5D summary index at T1 was adjusted; 
In the Model 3 and 4, EQ-5D summary index at T1 and change in the index were added as main predicators 
separately, then HADS-A/HADS-D at T1 was adjusted. We tested the full models by including both main predic-
tors, outcome at T1, and demographical and diabetes characteristics as predicators. Finally, a cross-lagged panel 
structural equation modelling (SEM) was used to assess the longitudinal association among anxiety, depression 
and HRQoL (EQ-5D summary index) at T1 and T2. All variables were modeled as observed variables with error 
terms included to correct for external factors that may contribute to observed effects. We used a number of fit 
indices to evaluate the model: chi-square (Χ2)/degrees of freedom (df) of 2.00 or below, Comparative Fit Index 
(CFI) values of 0.90 or above, and root mean square error of approximation (RMSEA) values of 0.06 or below 
were used as standards of acceptable fit29.
Results
Demographic and diabetes characteristics. At T1, among 305 patients who completed the screening 
questions, 131 (42.9%) completed the survey for this study (Table 1). The respondents were aged from 23 to 81 
years (mean: 54 years). The majority were male (50.4%), Dutch inhabitants (73.6%), living with type 2 diabetes 
(58.6%) for over 19 years, with a paid employment (43.2%) or social welfare (including retirement) (40%), had 
received education lower than the college level (71.5%). At T2, among 131 eligible respondents, 113 (86.3%) 
patients completed the second survey and 18 (13.7%) were lost to follow-up. No statistically significant differences 
were found regarding the demographic and diabetes characteristics between T1 and T2 (P > 0.05).
Prevalence of anxiety, depression and HRQoL. Of all respondents at T1 (Table 2), 36 (27.5%) had 
anxiety symptoms and 26 (19.8%) had depression symptoms. Twenty (15.3%) patients had both depression and 
anxiety symptoms. Regarding HRQoL, over half of the diabetes patients reported that they had experienced 
T1 (n = 131) T2 (n = 113) P-
valuen % Mean (SD) n % Mean (SD)
Gender
Male 66 50.4 57 50.4 1.000
Female 65 49.6 56 49.6
Diabetes type
Type 1 46 41.4 41 42.7 0.982
Type 2 65 58.6 55 57.3
Age (year) 54.0 (13.1) 54.4 (12.7) 0.776
Duration of living with diabetes (year) 19.4 (14.3) 19.9 (14.7) 0.807
Employment
Paid employment 54 43.2 46 43.4 0.934
Social welfare or retirement 50 40.0 44 41.5
Unemployment 21 16.8 16 15.1
Education level
Low (LTS, VMBO, MAVO, VMBO-t) 54 41.5 47 42.0 0.910
Intermediate (MTS, HBS, HAVO, VWO) 39 30.0 31 27.7
High (HBO, WO) 37 28.5 34 30.4
Ethnicity
Majority/no migrant 95 73.6 87 78.4 0.566
1st generation migrant 24 18.6 15 13.5
2nd generation migrant 10 7.8 9 8.1
Table 1. Demographic and diabetes characteristics of patients with diabetes at T1 and T2. Note: LTS, lage 
technische school; VMBO, voorbereidend middelbaar beroepsonderwijs; MAVO, middelbaar algemeen 
voortgezet onderwijs; VMBO-t, voorbereidend middelbaar beroepsonderwijs-theoretical; MTS, middelbaar 
technische school; HBS, hoge burger school; HAVO, hoger algemeen voortgezet onderwijs; VWO, 
voorbereidend wetenschappelijk onderwijs; HBO, hoger beroeps opleiding; WO, wetenschappelijk onderwijs.
4Scientific RepoRtS |         (2020) 10:8307  | https://doi.org/10.1038/s41598-020-57647-x
www.nature.com/scientificreportswww.nature.com/scientificreports/
problems in usual activities (53.4%), pain (74.8%) and cognition (51.9%). The mean EQ VAS score was 70.1 (SD: 
20.1) out of 100 (best health), the averaged EQ-5D summary index was 0.73 (SD: 0.27) out of 1 (best HRQoL). 
Among 113 respondents who filled out the survey both at T1 and T2, 61 (46.6%) reported less problems on the 
EQ-5D dimensions at T2 while 49 (37.4%) reported more problems on the EQ-5D dimensions at T2. No statisti-
cally significant differences were found between T1 and T2 regarding anxiety symptoms, depression symptoms, 
and all dimensions of HRQoL (P > 0.05).
Negative association between anxiety/depression and HRQoL within time intervals. Fig. 1 
shows that, within both time intervals, diabetes patients with a higher score in the anxiety subscale had experi-
enced significantly more problems on all EQ-5D + C dimensions in general, i.e. mobility, self-care, usual activi-
ties, pain/discomfort and cognition (P < 0.05). However, respondents who had experienced extreme problems in 
mobility, self-care, usual activities and pain/discomfort reported fewer anxiety symptoms than those experienced 
moderate or severe problems (P < 0.05). The association between anxiety and all EQ-5D + C dimensions is sim-
ilar to the association between depression and the EQ-5D + C dimensions within both time intervals, except for 
the non-linear association between depression and self-care at T1.
Regarding overall HRQoL in diabetes patients, those with more anxiety symptoms had a significantly lower 
overall rate at EQ VAS at both T1 (P < 0.01; R2 = 0.27) and T2 (P < 0.01; R2 = 0.35). The linear regression models 
using depression score to predict EQ VAS rate are similar to using anxiety as predictor (R2 = 0.29 at T1; R2 = 0.50 
at T2).
Effects of anxiety and depression on HRQoL over time, and vice versa. Table 3 shows that the 
EQ-5D summary index at T2 reflected the change in anxiety and depression symptoms between time intervals 
(B = −0.03) more than baseline anxiety (B = −0.01) and depression symptoms (B = −0.02). Both of the changes 
in anxiety and depression symptoms between T1 and T2, as well as depression at T1, significantly explained the 
EQ-5D summary index at T2 (P < 0.05), correcting for baseline EQ-5D summary index, patient’s demographic 
and diabetes characteristics in the Model 1 (R2 = 0.467) and Model 2 (R2 = 0.561). At univariate models: Patients 
who were living with diabetes type 1, employed, higher education background, and a majority ethnicity had sig-
nificantly higher EQ-5D Index, thus better HRQoL (B > 0; P < 0.05). However, none of those characteristics were 
significantly associated with EQ-5D index in the multivariable models (P > 0.05).
T1 (n = 131) T2 (n = 113) P-
valuen % Mean (SD) n % Mean (SD)
Anxiety and depression
HADS – Anxiety 
(0–21) 5.81 (4.12) 5.66 (4.20) 0.778
Cut-off score:8 36 27.5 31 27.9 0.938
HADS – Depression 
(0–21) 4.64 (3.94) 4.80 (4.33) 0.763
Cut-off score:8 26 19.8 26 23.4 0.500
EQ-5D-5L
Mobility 1.76 (1.01) 1.70 (0.97) 0.678
  No problem (1) 73 55.7 63 56.8 0.897
  Problems (2–5) 58 44.3 48 43.2
Self-Care 1.18 (0.58) 1.15 (0.47) 0.760
  No problem (1) 116 88.5 97 88.2 1.000
  Problems (2–5) 15 11.5 13 11.8
Usual activities 1.92 (1.07) 1.95 (1.01) 0.773
  No problem (1) 61 46.6 46 41.4 0.439
  Problems (2–5) 70 53.4 65 58.6
Pain/discomfort 2.24 (0.99) 2.09 (0.92) 0.219
  No problem (1) 33 25.2 32 29.1 0.561
  Problems (2–5) 98 74.8 78 70.9
Anxiety/depression 1.69 (1.00) 1.58 (0.79) 0.339
  No problem (1) 76 58.0 64 58.2 1.000
  Problems (2–5) 55 42.0 46 41.8
Additional: Cognition 1.72 (0.84) 1.69 (0.75) 0.798
  No problem (1) 63 48.1 50 45.5 0.699
  Problems (2–5) 68 51.9 60 54.5
EQ-5D Index (0–1) 0.73 (0.27) 0.77 (0.22) 0.220
  EQ VAS (0–100) 70.1 (20.1) 68.8 (21.5) 0.631
Table 2. Hospital Anxiety and Depression Scale (HADS) scores, percentage of reported problems on the 
European Quality of Life at 5 dimensions (EQ-5D) and extended cognitive dimension, the mean score of 
patients with diabetes for EQ-5D summary score and index and EQ visual analogue scale (VAS) at T1 and T2.
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Similarly, the change in EQ-5D summary index between T1 and T2 significantly explained the anxiety and 
depression scores at T2 (P < 0.05), correcting for baseline anxiety and depression scores, patient’s demographic 
and diabetes characteristics in the Model 3 (R2 = 0.707) and Model 4 (R2 = 0.720). The anxiety score at T2 sig-
nificantly reflected the change in EQ-5D index between time intervals (B = −6.50) more than baseline EQ-5D 
index (B = −3.14), while depression at T2 reflects the change in HRQoL (B = −7.24) as much as HRQoL at T1 
(B = −7.43). Patients who were employed and living with a majority ethnicity were less likely to have anxiety 
symptoms, while those who were employed, with lower education background, and a majority ethnicity were less 
likely to have depression symptoms (B < 0; P < 0.05); However, none of those characteristics were significantly 
associated with anxiety and depression scores in the multivariable models (P > 0.05).
Figure 1. The mean anxiety and depression subscale scores and its 95% confidence interval (CI) and the level of 
severity of problems (from left to right: weakest to strongest problems) for each of the EQ-5D dimensions and 
extended cognitive dimension at T1 and T2. Note: EQ-5D, the European Quality of Life at 5 dimensions.
Crude model
Adjusted model for 
baseline outcome *
Adjusted model for 
baseline outcome and 
confounders # Adjusted 
R2Β (SE) P Β (SE) P Β (SE) P
Outcome: EQ-5D Index at T2
Model 1 Predictor
Anxiety at T1 −0.03 (0.01) <0.001 0.00 (0.01) 0.949 −0.01 (0.01) 0.121 0.467
Change in Anxiety −0.01 (0.01) 0.132 −0.02 (0.01) <0.001 −0.03 (0.01) <0.001
Model 2 Predictor
Depression at T1 −0.03 (0.01) <0.001 0.00 (0.01) 0.477 −0.02 (0.01) 0.025 0.561
Change in Depression −0.02 (0.01) 0.014 −0.02 (0.00) <0.001 −0.03 (0.01) <0.001
Outcome: Anxiety at T2
Model 3 Predictor
EQ-5D Index at T1 −9.49 (1.35) <0.001 −1.55 (1.39) 0.263 −3.14 (1.74) 0.072 0.707
Change in EQ-5D Index −0.04 (2.04) 0.986 −4.78 (1.36) <0.001 −6.50 (1.46) <0.001
Outcome: Depression at T2
Model 4 Predictor
EQ-5D Index at T1 −12.4 (1.19) <0.001 −6.65 (1.64) <0.001 −7.43 (1.87) <0.001 0.720
Change in EQ-5D Index 0.52 (2.12) 0.807 −4.07 (1.51) 0.007 −7.24 (1.43) <0.001
Table 3. Linear models of anxiety/depression at T1 and change in anxiety/depression over time predicting 
the EQ-5D summary index at T2 (Model 1 and 2); and of the EQ-5D summary index at T1 and change in 
the summary index over time predicting anxiety/depression at T2 (Model 3 and 4). Note: B, standardized 
coefficient; SE, standard error; EQ-5D, the European Quality of Life at five dimensions; Higher score on 
EQ-5D index indicate better quality of life in mobility, self-care, usual activities, pain/discomfort and anxiety/
depression, while higher scores on anxiety and depression subscales indicates more anxiety/depression 
symptoms. *Interactions between baseline outcome and predictor were excluded in the model, as no statistically 
significant interactions were found (P > 0.05). #Model adjusted for demographic and diabetes characteristics, 
including gender, age, diabetes type, diabetes duration, employment status, education level, ethnicity; both of 
the baseline predictor and change in predictor were included in the model.
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Longitudinal association between anxiety/depression and HRQoL with directions. We fit-
ted our longitudinal data in a cross-lagged model with the hypothesis that there are bi-directional pathways 
of negative associations between anxiety symptoms and HRQoL, as well as depression symptoms and HRQoL, 
among adult patients with diabetes (Fig. 2). This model reached the standard of acceptable fitness (x2/df = 1.102, 
P = 0.256; CFI = 1.000, RMSEA = 0.030). Statistical significance was found in all the path coefficients (P < 0.05). 
Overall at T2, 46.9% of the variance in anxiety, 65.8% of the variance in depression and 86.0% of the variance in 
HRQoL were explained by the model.
Discussion
This longitudinal study points at bi-directional negative associations between anxiety as well as depression symp-
toms and health-related quality of life (HRQoL) among adult patients with diabetes. Despite receiving diabetes 
care, our results during follow-up of the patients suggest direct effects of changes in anxiety and depression symp-
toms on HRQoL over time, as well as a direct effect of changes in HRQoL on anxiety and depression symptoms. 
In addition, this study shows that symptoms of anxiety and depression are common in diabetes patients, and 
HRQoL is suboptimal in general for patients with diabetes.
Anxiety and depression symptoms prevalence rates found in this study (27.5% and 19.8%) are almost twice as 
low compared to those found in another recent longitudinal study by Tonje and colleagues (47% and 38%)30. Both 
used the same instrument and thresholds to measure anxiety and depression; however, Tonje’s study included 
patients living with both diabetes and gastroparesis symptoms in Norway, which may explain the discrepancy. 
Our identified prevalence rate of depression symptoms (19.8%) is very similar to the finding of a previous review 
on epidemiology of depression in people with type 2 diabetes (19.1%)31. Also, we found that over half of the 
diabetes patients who had anxiety symptoms lived also with depression symptoms. This result is expected as 
symptoms of depression and anxiety often overlap and anxiety-depression comorbidity has been found among 
various populations32,33.
Unemployed patients with diabetes of a minority ethnic background and lower HRQoL were susceptible 
to develop anxiety symptoms; while those who were unemployed with higher education of a minority ethnic 
background and lower HRQoL were subject to depression symptoms. Nevertheless, we found that the change 
in HRQoL between time intervals was the most significantly associated with anxiety and depression symptoms 
developed over time, independent of all measured social demographics and baseline anxiety/depression level. 
Mood may be influenced by HRQoL through anxiety and depression systems with factors like social support 
and support utilization, which have a proven relationship with changing HRQoL34 and a proven association with 
psychological adjustment that influences risks of anxiety and depression35. This emphasizes the importance of 
efforts to maximize HRQoL in order to prevent anxiety and/or depression in diabetes. Future efforts to prevent 
anxiety and depression in diabetes care should take into consideration factors influencing HRQoL. For instance, 
pay attention to patients with diabetes who are struggling with insulin therapy, obesity and suffer from diabetic 
complications, low self-efficacy and social support, which all associate with suboptimal HRQoL36–38.
With regard to HRQoL status itself, we identified the average index score 0.73 at baseline, which is identical 
to a previous study using the same instrument among Dutch patients with type 2 diabetes36. Similarly, the major-
ity of the patients with diabetes in this study reported problems in daily activities, pain and cognition, which is 
consistent with previous empirical findings in the US39. The reported mean EQ VAS rating was lower than that 
among a general population of the Netherlands (70.1 VS 77.7)40. The identified suboptimal HRQoL highlights 
an urgent need of interventions to improve the HRQoL in our patients with diabetes. Previous studies indicated 
social demographics, like ethnicity41, age, sex and occupation42, as possible determinants of HRQoL. However, 
we found that changes in anxiety and depression, as well as baseline depression symptoms, were the most signif-
icantly associated with HRQoL over time and independent of all measured social demographics. This indicates 
that interventions to prevent anxiety and depression could be beneficial to improve HRQoL in diabetes care. An 
Figure 2. The cross-lagged model hypothesized to analyze the longitudinal association among anxiety, 
depression and health-related quality of life (HRQoL) summary index. Note: HRQoL is measured by EQ-5D 
summary index with higher score on EQ-5D index indicating better quality of life in mobility, self-care, usual 
activities, pain/discomfort and anxiety/depression; Numbers above arrows indicate standardized correlation 
coefficients; Thick arrows indicate the paths of interest, which are the bidirectional, longitudinal paths between 
anxiety/depression and HRQoL. The overall model fit was x2/df = 1.102; CFI = 1.000, RMSEA = 0.030.
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important way to reduce unrecognized depression and anxiety is by advocating depression screening programs in 
diabetes care, particularly for patients with lower socioeconomic status and patients without a previous diagnosis 
of major depressive disorder43,44. Future efforts to improve HRQoL of diabetes patients should take into account 
other determinants of anxiety and depression. For instance, patients who suffer from central obesity, neuropathy, 
peripheral vascular disease, diabetic foot disease and pill burden are at risk for depression45. Poor glycemic con-
trol46, systolic blood pressure and fasting blood triglycerides47 may be indicators of a combination of depressive 
and anxiety symptoms in diabetes patients.
An unexpected yet interesting result is that the respondents who reported extreme problems in mobility, 
self-care, daily activities and pain reported fewer anxiety symptoms than those experienced moderate or severe 
problems. A possible explanation is resilience – patients who have been suffering from diabetes with complica-
tions for a long period may know better what they are dealing with, and have developed a better capacity to navi-
gate their way to the psychological resources that sustain their mental well-being or accepting their situation48,49. 
Another explanation may be attrition - patients with severe health problems and anxiety and/or depression have 
already died, thus were not recruited by this study50.
This study investigated the prevalence of anxiety, depression and HRQoL among a population of adults with 
diabetes. To the best of our knowledge, this is the first longitudinal study evaluating the bi-directional associa-
tion between anxiety symptoms and HRQoL, as well as depression symptoms and HRQoL, for diabetes patients. 
The questionnaires we used to measure symptoms of anxiety, depression and HRQoL had been validated widely 
and the results are comparable globally. In addition, considering anxiety/depression is one of the dimensions 
of EQ-5D, we investigated the associations of HRQoL using not only the EQ-5D summary index, but also five 
levels of problems for all dimensions besides anxiety/depression. Although 13.7% of the respondents were lost 
to follow-up, no significant differences in social demographics of respondents were found between two time 
points. Our study has several limitations. First, due to the nature of self-reported data, our information is likely 
influenced by recall bias and social desirability bias51. Second, we did not take into account the impact of the 
screening program conducted between T1 and T2, given the fact that we did not find any statistically significant 
difference with regards to the prevalence rates of anxiety, depression and HRQoL between the measured time 
points. Of course, three months of follow-up is not likely to have adequate power to detect such differences52. 
Third, we tested the direct paths between anxiety, depression and HRQoL in time, without considering possible 
mediators like socio-demographical characteristics, diabetes type and perceived social support, for instance, that 
might tangle those paths53. Finally, we are lacking information regarding differences between our respondents 
and those who did not completed the survey during the recruitment of participates, thus our sample may not be 
representative of all adult patients with diabetes, and we cannot exclude effects regarding order or repetition of 
questions in repeated surveys.
Our research results provide direct evidence to support guidelines recommending mental health screening in 
diabetes care, and promote efforts improving HRQoL for patients with diabetes in general. An important clinical 
implication is that efforts to decrease anxiety and/or depression could significantly improve HRQoL of patients 
with diabetes and should be tested and eventually added to diabetes care. Likewise, interventions to improve 
HRQoL in diabetes care are able to assist in preventing patients from developing anxiety and depression dur-
ing diabetes management. Adopting an evidence-based and population-tailored collaborative care model might 
have potential to improve both54. We recommend future studies to investigate the associations between anxiety/
depression and HRQoL in a prospective design with a follow-up period longer than three months, and to include 
more potential determinants besides social demographics, such as timing of anxiety/depression onset, obesity, 
insulin therapy and lifestyle factors36, and explore their effects in marginal models (e.g. Generalized Estimating 
Equations) or conditional models (e.g. Generalized Linear Mixed Models)55 to optimize and test future preventive 
measures.
Data availability
The datasets generated during and/or analyzed during the current study are not publicly available due to the 
terms of consent to which the participants agreed, but are available from the corresponding author on reasonable 
request.
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